BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating ...
Please provide your email address to receive an email when new articles are posted on . Facial identity discrimination accuracy decreased by 20.4% under low luminance for those with central vision ...
Please provide your email address to receive an email when new articles are posted on . Laru-zova demonstrated a positive safety profile and early efficacy in improving low luminance visual acuity in ...
VIENNA, Austria — Compared with subcutaneous interferon β-1a (IFNB-1a; Rebif/EMD Serono/Pfizer), treatment with alemtuzumab (Lemtrada, Genzyme/Sanofi) improved visual outcomes in treatment-naive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results